Novellia

The AI does the load bearing work of the data product: stitching records from more than 50,000 provider sources into structured longitudinal journeys and cleaning them to surface signals that snapshot datasets miss. Held back from A because the differentiated asset is the patient consented collection channel itself. A competitor with the same models but purchased broker data would have a materially worse product, which means the moat is provenance as much as inference.

Commercial validation is real, with the company reporting customers among a majority of the top 10 to 15 global pharmaceutical companies, and one described application involved analyzing a safety signal for a breast cancer drug where the platform found a lower incidence of a suspected adverse event than previously believed. However that account is vendor described without published methodology, and no peer reviewed validation of the dataset's completeness or representativeness was retrieved. Patient contributed cohorts also carry self selection characteristics that a research buyer must assess directly.

Consent architecture is the product thesis rather than a compliance layer. Patients aggregate their own records under the 21st Century Cures Act access rights and separately choose whether to contribute de identified data to research, and the company contrasts this explicitly with third party brokers stitching together claims and hospital records without patient participation. Data provenance is stated as direct from the patient with no tokenization or third party guesswork. Consent obtained at the source is the strongest stewardship position available in real world data.

Retrieval breadth is the core competency: connections to more than 50,000 US healthcare providers spanning Epic, Oracle Health, athenahealth, Quest Diagnostics, and the VA, with paper record capture by camera as a fallback. This is patient mediated access under federal interoperability rules rather than institutional integration, a materially different and broader path than negotiating system by system.

The structure is clearly disclosed even though amounts are not: the patient application is free, and revenue comes from de identified data and insight products sold to pharmaceutical and diagnostics customers. A buyer understands exactly how the two sides relate, which is more than most data vendors disclose. No rate card published.